Ottobock sets final offer price at EUR 66.00 per share

EQS-News: Ottobock SE & Co. KGaA / Key word(s): IPO Ottobock sets final offer price at EUR 66.00 per share 07.10.2025 / 20:00 CET/CEST The issuer is solely responsible for the content of this announcement. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.

Ottobock sets final offer price at EUR 66.00 per share

Duderstadt, 07 October 2025

 

• Total offer volume amounts to EUR 807,587,418.00 and comprises the placement of 1,515,151 newly issued bearer shares, 9,125,000 existing bearer shares, as well as 1,596,022 bearer shares in connection with an over-allotment option
• Final offer price implies a market capitalization of approximately EUR 4.2 billion
• Free float expected to amount to 19.12%, current shareholders expected to retain at least 80.88% of the share capital
• First day of trading on the regulated market (Prime Standard) of the Frankfurt Stock Exchange scheduled for 9 October 2025

 

Ottobock SE & Co. KGaA (the “Company”) – the global MedTech champion of the Custom Orthotics and Prosthetics (O&P) industry – has set the final price for its initial public offering (the “IPO”) today at EUR 66.00 per share.

A total of 12,236,173 shares are being placed with investors, comprising 1,515,151 newly issued bearer shares from a capital increase against cash contributions, 9,125,000 existing bearer shares from the holdings of Näder Upside Vermögensverwaltungs GmbH (the “Selling Shareholder”) and 1,596,022 additional existing bearer shares from the holdings of the Selling Shareholder in connection with an over-allotment (the “Greenshoe Option”).

Oliver Jakobi, CEO of Ottobock, said: “The IPO marks an important milestone for Ottobock. For more than 100 years, the Company has stood for innovation and responsibility towards the people we serve. With the IPO, we are creating the foundation to carry this tradition into the future – with investments in cutting-edge technologies, sustainable growth, and the clear ambition to set new standards in Human Bionics.”